Posts Tagged ‘early-stage Alzheimer’s’
Hopes and Questions raised by Alzheimer’s drug Leqembi (lecanemab)
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing the medication to patients, possibly by summer’s end or early autumn. It’s a…
Read MoreOn physical activity, neuroplasticity, depression, screen time, neuromodulation and more
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring this time eight scientific reports and industry resources plus a few fun brain teasers. #1. Study finds ultimate hack to protect teen brains from harmful screen time: Exercise (and good role-modeling): “Girls who spent less than an hour on screens and boys who spent less than…
Read MoreSix guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease
The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging. After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies that…
Read More